Possible impact of revisions in disc diffusion breakpoints for aminoglycosides and piperacillin/tazobactam in the 33rd edition of CLSI M100 document on clinical reporting and use in Indian settings with low susceptibility-Reference-Cited by-同舟云学术

Possible impact of revisions in disc diffusion breakpoints for aminoglycosides and piperacillin/tazobactam in the 33rd edition of CLSI M100 document on clinical reporting and use in Indian settings with low susceptibility

Published:2024-05 Issue: Volume:49 Page:100602
ISSN:0255-0857
Container-title:Indian Journal of Medical Microbiology
language:en
Short-container-title:Indian Journal of Medical Microbiology

Author:

Aggarwal Prabhav,Saxena Sonal,Nagi Nazia

Publisher

Elsevier BV

Reference15 articles.

1. Performance standards for antimicrobial susceptibility testing,2023

2. Aminoglycoside therapy in infectious diseases;Poulikakos;Expet Opin Pharmacother,2013

3. Clinical and Laboratory Standards Institute (CLSI). AST news update June 2023: New! CLSI M100-ED33: Updated aminoglycoside breakpoints for Enterobacterales and pseudomonas aeruginosa. Available at: ≤https://clsi.org/about/blog/ast-news-update-june-2023-new-clsi-m100-ed33-updated-aminoglycoside-breakpoints-for-enterobacterales-and-pseudomonas-aeruginosa.> Accessed September 30, 2023.

4. 2562. re-appraisal of aminoglycoside (AG) susceptibility testing breakpoints based on the application of pharmacokinetics–pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data;Bhavnani;Open Forum Infect Dis,2018

5. Performance standards for antimicrobial susceptibility testing,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human breast milk isolated lactic acid bacteria: antimicrobial and immunomodulatory activity on the Galleria mellonella burn wound model;Frontiers in Cellular and Infection Microbiology;2024-09-06